Data presented at conference
March 27 2007 - 5:00AM
RNS Non-Regulatory
VASTox plc
27 March 2007
VASTox plc
("VASTox" or "the Company")
MAJOR PHARMACEUTICAL COMPANIES PRESENT VASTOX DATA AT LEADING INTERNATIONAL
CONFERENCE
Oxford, UK, 27 March 2007 - VASTox plc (AIM: VOX) today announced that Roche,
Bayer-Schering and Merz will present scientific data gathered using VASTox's
proprietary zebrafish technology platform at the Society of Toxicity Annual
Meeting being held in Charlotte, North Carolina between the 25-29 March 2007.
In 2006, VASTox entered into a joint pilot study with the three European
pharmaceutical companies to test if a known set of compounds were teratogenic
and would therefore cause malformations in a developing embryo. Using VASTox's
proprietary 'vivo(TM)' predictive toxicology platform, the compounds were
blind-screened in zebrafish with the results proving to be highly predictive for
this toxic effect. The results from this study will be displayed during a
poster symposium at the meeting.
The Society of Toxicology Annual Meeting is the largest toxicology meeting and
exhibition in the world, attracting approximately 6,000 scientists from
industry, academia and government. The data being presented at the conference
will allow VASTox to highlight to a global audience its innovative technology
platform, which has the potential to reduce failure rates and cost in drug
discovery programmes.
Following this successful pilot study, VASTox is developing plans to expand the
original collaboration to include additional leading pharmaceutical companies.
Steven Lee, PhD, CEO, commented: "The completion of the successful pilot study
with these leading pharmaceutical companies provides further industry validation
of the benefits our world-leading zebrafish technology platform brings to drug
discovery programmes. The use of zebrafish within drug discovery has
significant potential to both reduce the cost and attrition rates in drug
discovery and also reduce the number of higher animal models used in regulatory
testing."
- ends -
For more information, please contact:
VASTox
Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951
Darren Millington, Chief Financial Officer
Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571
About VASTox's zebrafish platform
VASTox's zebrafish (Danio rerio) technology platform allows high-volume,
high-content screening of small molecule drug candidates. This approach
generates in vivo data, which can be used to determine key characteristics of
potential drug candidates. These data are highly predictive of efficacy and
toxicity in humans, reducing the risk of failure in discovery programmes, while
having the potential to dramatically decrease the time and cost of drug
discovery and development.
VASTox has developed a wide range of validated toxicology screens, the
'vivo(TM)' screening platform, to assess compound safety and potential side
effects. These include:
* Acute toxicity
* Cardiotoxicity
* Hepatotoxicity
* Myelotoxicity
* Embryotoxicity & Teratogenicity
About VASTox plc
VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.
VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.
VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.
The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX
Further information about the company is available at www.vastox.com
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.
Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements include (factors
included in this presentation) and regional, national, global political,
economic, business, competitive, market and regulatory conditions.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPUUMPWUPMGQQ
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024
